PF-AKT400 - CAS 1004990-28-6
Catalog number: 1004990-28-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H22F2N6O
Molecular Weight:
400.43
COA:
Inquire
Targets:
Akt
Description:
PF-AKT400 is an APT competitor inhibitor of AKR kinase. This compound was first described as compound 42 in J. Med. Chem. 2010, 53, 4615–4622 by a group of Pfizer scientists. The paper describes the design and synthesis of novel, ATP-competitive Akt inhibitors from an elaborated 3-aminopyrrolidine scaffold. Key findings include the discovery of an initial lead that was modestly selective and medicinal chemistry optimization of that lead to provide more selective analogues. Analysis of the data suggested that highly lipophilic analogues would likely suffer from poor overall properties. Central to the discussion is the concept of optimization of lipophilic efficiency and the ability to balance overall druglike propeties with the careful control of lipophilicity in the lead series. Discovery of the nonracemic amide series and subsequent modification produced an advanced analogue that performed well in advanced preclinical assays, including xenograft tumor growth inhibition studies, and this analogue was nominated for clinical development. The compound has no official name, has molecule weight 400.43. We temporally call this compound as PF-AKT400.
Synonyms:
PF-AKT400; PFAKT400; Lig1; Lig-1; Lig 1; PF AKT400; AKT-0286; AKT 0286; AKT0286
MSDS:
Inquire
InChIKey:
MOZRQQTUYAYCQT-FQEVSTJZSA-N
InChI:
InChI=1S/C20H22F2N6O/c1-2-12-8-24-17-16(12)18(27-11-26-17)28-6-5-20(23,10-28)9-25-19(29)14-4-3-13(21)7-15(14)22/h3-4,7-8,11H,2,5-6,9-10,23H2,1H3,(H,25,29)(H,24,26,27)/t20-/m0/s1
Canonical SMILES:
CCC1=CNC2=C1C(=NC=N2)N3CCC(C3)(CNC(=O)C4=C(C=C(C=C4)F)F)N
Current Developer:
Pfizer
1.Binding selectivity studies of PKBα using molecular dynamics simulation and free energy calculations.
Chen SF;Cao Y;Chen JJ;Chen JZ J Mol Model. 2013 Nov;19(11):5097-112. doi: 10.1007/s00894-013-1997-3. Epub 2013 Oct 2.
Designing selective protein kinase B (PKB/Akt) inhibitor is an area of intense research to develop potential anticancer drugs. In the present study, the molecular basis governing PKB-selective inhibition has been investigated using molecular dynamics simulation. The binding free energies calculated by MM/PBSA gave a good correlation with the experimental biological activity and a good explanation of the activity difference of the studied inhibitors. The decomposition of free energies by MM/GBSA indicates that the ethyl group on pyrrolo[2,3-d]pyrimidine ring of inhibitor Lig1 (N-{[(3S)-3-amino-1-(5-ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-yl]-methyl}-2,4-difluoro-benzamide) is an important contributor to its PKBα selectivity due to its hydrophobic interaction with the side chain of Thr291 in PKBα. The substituted groups on the pyrrolidine ring of Lig1 also show a strong tendency to mediate protein-ligand interactions through the hydrogen bonds formed between the amino or amide groups of Lig1 and the carboxyl O atoms of Glu234, Glu278, and Asp292 of PKBα. It was reported that there are only three key amino acid differences between PKBα (Thr211, Ala230, Met281) and PKA (Val104, Val123, Leu173) within the clefts of ATP-binding sites.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Akt Products


CAS 1191951-57-1 PHT-427

PHT-427
(CAS: 1191951-57-1)

PHT-427 is an AKT inhibitor that inhibits AKT and PDPK1 at low micromolar concentrations in numerous cancer cell lines and exhibits good oral anti-tumor activit...

CAS 1039455-84-9 COTI-2

COTI-2
(CAS: 1039455-84-9)

COTI-2 is an p53 gene activator and the PI3K/AKT/mTOR pathway inhibitor. COTI-2 induces apoptosis and suppresses proliferation of a wide variety of human cancer...

CAS 885499-61-6 CCT128930

CCT128930
(CAS: 885499-61-6)

CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine co...

CAS 871361-88-5 SC66

SC66
(CAS: 871361-88-5)

SC66 is a novel and potent AKT inhibitor, which reduced cell viability in a dose- and time-dependent manner, inhibited colony formation and induced apoptosis in...

CAS 28755-03-5 3CAI

3CAI
(CAS: 28755-03-5)

3CAI is an orally active, potent and specific allosteric inhibitor of Akt1 and Akt2 that directly binds to Ak1 and Akt2 in an ATP noncompetitive manner.

CAS 1047644-62-1 Afuresertib

Afuresertib
(CAS: 1047644-62-1)

Afuresertib, also known as GSK2110183,  is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineo...

CAS 893422-47-4 Akt1 and Akt2-IN-1

Akt1 and Akt2-IN-1
(CAS: 893422-47-4)

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 and Akt2 with the IC50 of 3.5 nM and 42 nM respectively. It has potent and balanced activity. It is depend...

MK-2206 hydrochloride
(CAS: 1032349-77-1)

MK-2206 hydrochloride is the hydrochloride form of MK-2206, which is an allosteric inhibitor of Akt and an orally bioavailable allosteric inhibitor of the serin...

Chemical Structure

CAS 1004990-28-6 PF-AKT400

Quick Inquiry

Verification code

Featured Items